Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Sept 2024

Grazini Ursula, Markovets Aleksandra, Ireland Lucy, O'Neill Daniel, Phillips Benjamin, Xu Man, Pfeifer Matthias, Vaclova Tereza, Martin Matthew J, Bigot Ludovic, Friboulet Luc, Hartmaier Ryan, Cuomo Maria E, Barry Simon T, Smith Paul D, Floc'h Nicolas

Abstract excerpt

PURPOSE: Osimertinib is an EGFR tyrosine kinase inhibitor indicated for the treatment of EGFR-mutated (EGFRm)-driven lung adenocarcinomas. Osimertinib significantly improves progression-free survival in first-line-treated patients with EGFRm advanced non-small cell lung cancer (NSCLC). Despite the durable disease control, the majority of patients receiving osimertinib eventually develop disease progression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Indoles

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Pyrroles

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38630555
DOI: 10.1158/1078-0432.CCR-23-2540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.PMID 38630555Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibSemantic proximity Read ↗

PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.Semantic proximity Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Semantic proximity Read ↗

P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read ↗

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read ↗

Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC.Semantic proximity Read ↗

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.Semantic proximity Read ↗

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read ↗

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.